Articles related to BIOMARKERS

The recent study from CTAD 2023 has demonstrated the potential of p-tau217 as a promising biomarker for preclinical Alzheimer’s disease. This finding could significantly enhance our ability to detect Alzheimer’s at its earliest stages and initiate timely interventions.

Discover how Labcorp’s new ATN Profile can revolutionize your approach to diagnosing Alzheimer’s disease.

Don’t miss this crucial update on how biomarker-guided first-line treatment can substantially improve survival rates in advanced NSCLC patients.

Discover how MPO testing can offer a more comprehensive understanding of your patients’ health risks, including mortality beyond cardiovascular disease.

Discover how retinal assessments could offer a new diagnostic and treatment frontier in Parkinson’s disease, as recent findings demonstrate significant retinal degeneration correlated with disease progression.

Discover how finger-tapping patterns could aid early Alzheimer’s diagnosis, offering a cost-effective and less intrusive screening method.